Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis
2019; American Medical Association; Volume: 156; Issue: 1 Linguagem: Inglês
10.1001/jamadermatol.2019.3336
ISSN2168-6084
AutoresEric L. Simpson, Amy S. Paller, Elaine C. Siegfried, Mark Boguniewicz, Lawrence Sher, Melinda Gooderham, Lisa A. Beck, Emma Guttman‐Yassky, David M. Pariser, Andrew Blauvelt, Jamie Weisman, Benjamin Lockshin, Thomas Hultsch, Qin Zhang, Mohamed Kamal, John D. Davis, Bolanle Akinlade, Heribert Staudinger, Jennifer D. Hamilton, Neil M.H. Graham, Gianluca Pirozzi, Abhijit Gadkari, Laurent Eckert, Neil Stahl, George D. Yancopoulos, Marcella Ruddy, Ashish Bansal,
Tópico(s)Asthma and respiratory diseases
ResumoAdolescents with atopic dermatitis (AD) have high disease burden negatively affecting quality of life, with limited treatment options. The efficacy and safety of dupilumab, a monoclonal antibody, approved for treatment in adolescent patients with inadequately controlled AD, remain unknown in this patient population.
Referência(s)